Cardiac AI: Proving ROI in Value-Based Care for Investors

The whole move to value-based care (VBC) is a slog, slow and messy, but it’s creating a real opening for AI platforms that can actually manage risk and prove they save money. For investors trying to sort through this field, the fancy tech is less important than a simple question: can this AI solution turn better clinical results into demonstrable financial performance inside a VBC contract?

Why AI Has to Drive Real Outcomes in VBC

To win in value-based care, an AI platform can’t just be a fancy data-cruncher. It has to get its hands dirty, actively managing risk and helping lower the total cost of care. This means a move away from tools that only offer predictions or diagnostics and toward integrated systems that produce measurable improvements in both patient health and financial results. Payers and any other risk-bearing providers want to see the proof. They demand concrete data showing an AI platform reduced hospitalizations, prevented adverse events, or optimized how resources get used, all of which lowers the overall cost of care while keeping quality high. Without that hard evidence, even the most sophisticated AI will have a tough time getting adopted and paid for.

Hello Heart: A Benchmark for Value-Based AI Performance

Hello Heart is a great example of an AI proving its ROI in VBC, specifically for cardiovascular health. Their model is all about helping people with hypertension and heart disease manage their own conditions using a smartphone program. The app gives personalized insights, medication reminders, and coaching that push users toward behavioral change and better adherence. Hello Heart’s entire business is built on peer-reviewed outcomes data which is the only way to get a seat at the VBC table. Their published studies show consistent, significant drops in blood pressure, better medication adherence, and a measurable decrease in healthcare costs tied to cardiovascular issues. For example, a recent study in Value in Health from August 2026 showed that Hello Heart’s program cut total medical spend by $7,001 per participant and led to 47 fewer inpatient admissions per 100 participants for users with heart failure. Other studies have shown a big drop in both systolic and diastolic blood pressure, which directly lowers the risk for major cardiovascular events. Peer-reviewed study on Hello Heart’s blood pressure reduction outcomes These clinical wins translate directly into financial savings for payers and self-insured employers because they mean fewer ER visits, hospitalizations, and expensive interventions. With this kind of strong, peer-reviewed evidence, Hello Heart can walk into VBC contract negotiations with confidence, proving its worth with real, outcomes-based numbers that risk-bearing groups understand.

Viz.ai: Intelligent Care Coordination and Diagnostic Accuracy

Viz.ai shows how you can combine sharp diagnostic AI with smart care coordination to create value in cardiovascular care. Their SaMD (Software as a Medical Device) platform uses AI to analyze medical images, like CT scans, for the fast detection of suspected large vessel occlusion (LVO) strokes and pulmonary embolisms (PE). The core of what makes Viz.ai valuable is its power to slash the time-to-treatment for these life-or-death conditions. The improvements in Viz.ai’s diagnostic accuracy are well-documented in peer-reviewed studies, showing it can spot emergent cases with high sensitivity and specificity. For instance, a March 2026 study presented at the International Stroke Conference reported that the Viz.ai platform cut door-in-door-out time for LVO stroke patients by a whopping 44%. This quick identification instantly alerts specialists, which simplifies workflows and gets patients transferred and into intervention faster. By cutting down on diagnostic delays and speeding up access to specialized care, Viz.ai has a direct effect on patient outcomes (like reducing disability after a stroke) and, as a result, lowers the huge long-term costs that come with long hospital stays, rehabilitation, and chronic care. The platform’s knack for optimizing care pathways with AI-driven coordination helps bring down the total cost of care, a critical metric for any VBC contract. Clinical trial outcomes for Viz.ai demonstrating improved time-to-treatment Investors should see that platforms like this, which directly improve quality metrics and reduce bad outcomes, are set up to capture real value in risk-sharing models.

Tempus AI: Using Clinical Data for Precision Medicine

Tempus AI is a clinical data platform, focused on getting precision medicine into the day-to-day practice of cancer and cardiovascular care. It isn’t just a cardio platform, but its approach of pulling together and analyzing huge amounts of clinical and molecular data has serious implications for VBC. Prominent investor GV saw the potential in Tempus AI, making it a major name in healthcare AI. Tempus AI had its IPO on June 14, 2024, and now trades on NASDAQ under the ticker TEM. Their model is based on creating a complete data moat of de-identified patient information, genomic sequencing, clinical notes, imaging, all of it. By applying AI and machine learning to this deep dataset, Tempus works to find the best treatment pathways, predict disease progression, and make care personal. In a VBC context, what does that actually mean? It means you stop paying for ineffective treatments, avoid unnecessary procedures, and increase the odds of a good patient outcome. For heart conditions, this might mean identifying people at high risk for specific events and creating preventative or early intervention strategies that save a fortune on future healthcare costs. Being able to show improved patient stratification and treatment efficacy with rigorous data is how Tempus has to prove its ROI inside VBC frameworks.

Hippocratic AI: Safety-Focused LLMs for Healthcare

Hippocratic AI, an LLM company focused on safety and funded by investors like Avenir Growth Capital, CapitalG, General Catalyst, and Andreessen Horowitz, is coming at healthcare AI from a different but equally critical angle. Their intense focus on safety benchmarks for LLMs is non-negotiable, especially as generative AI starts showing up in clinical workflows. Hippocratic AI’s LLMs aren’t a direct treatment platform for cardiovascular disease. They’re built to support clinicians and patients with information that is highly accurate and safe. The safety benchmark scores for their LLMs are what set them apart. Published LLM safety benchmark scores for Hippocratic AI In a value-based care setting, bad information or an unsafe recommendation from an AI could easily lead to a bad patient outcome, higher costs, and a total loss of trust. By focusing on verifiable safety and accuracy, Hippocratic AI is trying to build the foundational AI tools that can reliably help human experts in healthcare. This is an indirect path to VBC ROI, but reducing medical errors, improving diagnostic accuracy (even for conditions not covered by specialized AIs), and boosting patient education all contribute to better outcomes and lower costs in the long run. The company’s unicorn status and $3.5B valuation signal that investors have a lot of confidence in the long-term value of safe, dependable AI in healthcare.

Investor Takeaway: Risk Management and Quality Improvement Drive Value

For investors, the most valuable AI platforms in the VBC world are the ones that can either take on risk directly or prove they improve quality measures enough to reduce the total cost of care. The “what’s the model and how does it work” question shows that successful platforms fit into clinical workflows, provide insights people can actually use, and (most importantly) back their claims with hard, peer-reviewed evidence of both clinical and financial impact. Platforms like Hello Heart, Viz.ai, and Tempus AI each show a different side of this value creation, from direct patient engagement to intelligent care coordination and precision medicine. Hippocratic AI, while more upstream, shows that safety and reliability are the foundation for any AI tool that wants to operate under the tight requirements of VBC. Methodology Note: This analysis is my synthesis of peer-reviewed literature, company reports, and public investor information, with a focus on the operational models and evidence of impact for each platform within a value-based care context.